Mouse anti Human CD5 FITC - CD19 PE
0519S
ApplicationsFlow Cytometry
Product group Antibodies
ReactivityHuman
TargetCD5
Overview
- SupplierNordic-MUbio
- Product NameMouse anti Human CD5 FITC - CD19 PE
- Delivery Days Customer7
- Application Supplier NotePBMC: Add 10 microl of MAB/10^6 PBMC in 100 microl PBS. Mix gently and incubate for 15 minutes at 2 to 8C. Wash twice with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. WHOLE BLOOD: Add10 microl of MAB/100 microl of whole blood. Mix gently and incubate for 15 minutes at room temperature 20C. Lyse the whole blood. Wash once with PBS and analyze or fix with 0.5% v/v of paraformaldehyde in PBS and analyze. See instrument manufacturers instructions for Lysed Whole Blood and Immunofluorescence analysis with a flow cytometer or microscope.
- ApplicationsFlow Cytometry
- Applications SupplierFlow Cytometry
- Category SupplierPrimary antibodies
- CertificationResearch Use Only
- ConjugateFITC, RPE
- Gene ID921
- Target nameCD5
- Target descriptionCD5 molecule
- Target synonymsCD5 antigen (p56-62); epididymis secretory sperm binding protein; LEU1; lymphocyte antigen T1/Leu-1; T1; T-cell surface glycoprotein CD5
- HostMouse
- IsotypeIgG1, IgG2a
- Protein IDP06127
- Protein NameT-cell surface glycoprotein CD5
- Scientific DescriptionCD5 FITC - CD19 PE
- Shelf life instructionSee expiration date on vial
- ReactivityHuman
- Reactivity SupplierHuman
- Reactivity Supplier NoteCD5=Derived from the hybridization of mouse NS-1/Ag4 myeloma cells with spleen cells of BALB/c mice immunized with human t-acute lymphoblastic leukemia (ALL) cells.
- Storage Instruction2°C to 8°C
- UNSPSC12352203
References
- 1. Anti-DNA Antibody Production by CD5+ and CD5- B Cells of Patients with Systemic Lupus Erythematosus. Suzuki,N., Sakane, T., Engleman, E.G. J. Clin. Invest. 1990 Ja;85(1):238-47. 2. Characteristics of CD11c+ CD5+ Chronic B cell Leukemias and the Identification of Novel Peripheral Blood B cell Subsets with Chronic Lymphoid Leukemia Immunophenotypes. Wormsley ,S.B., Baird, S.M., Gadol, N., Rai K.R., Sobol,R.E. Blood 1990 July. 76(1):123-30. 3. Stimulation of CD5 Enhances Signal Transduction by the T cell Antigen Receptor. Imboden, J.B., June, C.H., McCutcheon, M.A, Ledbetter ,J.A. J. Clin. Invest. 1990 Ja; 85(1):130-4 4. Surface Immunoglobulin Ligands and Cytokines Differentially Affect Proliferation and Antibody Production by Human CD5+ and CD5- B Lymphocytes. Nawata, Y., Stall, A.M., Herzenberg, L.A., Eugui, E.M., Allison,A.C., Int. Immunol. 1990;2(7):603-14 5. Evidence for Differential Responsiveness of Human CD5+ and CD5- B cell Subsets to T Cell Independent Mitogens. Zupo, S., Dono, M., .Azzoni ,L., Chiorazzi, N., Ferrarini, M. Eur. J. Immunol. 1991 Fe. 21(2):351-9 6. Functional Properties of CD19+ B Lymphocytes Positively Selected from Buffy Coats by Immunomagnetic Separation. Funderud, S., Erikstien, B., Asheim, H.C., Nustad ,K., Stokke, T., Blomhoff, H.K., Holte, H., Smeland, E.B. Eur. J. Immunol. 1990 Ja;20(1):201-6 7. Thymic B Cells from Myasthenia Gravis Patients are Activated B Cells. Phenotypic and Functional Analysis. Leprince, C., Cohen-Kaminsky, S., Berrih-Aknin, S., Vernet-Der Garabedian, B., Treton, D., Galanaud, P., Richard, Y., J. Immunol. 1990 Oct., 145(7):211522. 8. Prognostic Significance of CD34 Expression in Childhood B Precursor Acute Lymphocytic Leukemia: A Pediatric Onocology Group Study. Borowitz, M.J., Shuster, J.J., Civin, C.I., Carrol, A.J., Look, A.T., Behm, F.G., Land, V.J., Pullen, D.J., Crist, W.M. J. Clin. Onol. 1990 Au;8(8):1389-98. 9. Biphenotypic Acute Leukemia in Adults. Sulak, L.E., Clare, C.N., Morale, B.A., Hansen, K.L., Montiel, M.M. Am. J. Clin. Path. 1990 Ju;94(1):54-8. 10. Intersection of the Complement and Immune Systems: A Signal Transduction Complex of the B Lymphocyte Containing Complement Receptor type 2 and CD19. Matsumoto, A.K., Kopicky-Burd , J., Carter, R.H., Tuveson, D.A., Tedder, T.F., Fearon, D.T., J. Exp. Med. 1991 Jan. 173(1):55-64.